Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

ures.  Auxilium management will use these non-GAAP financial measures to monitor and evaluate our operating results and trends on an ongoing basis and internally for operating, budgeting and financial planning purposes.  Auxilium management believes the non-GAAP information will be useful for investors by offering them the ability to better identify trends in our business and better understand how management evaluates the business.  These non-GAAP financial measures that management will use will be presented in addition to results prepared in accordance with GAAP and should not be relied upon as an alternative to GAAP financial measures.  We currently anticipate that non-GAAP operating expenses and net income for 2013 will exclude stock-based employee compensation expense and imputed interest related to the convertible senior notes due in 2018.For 2013, Auxilium anticipates that:

  • Global net revenues will be in the range of $325 to $355 million;
  • Global Testim net revenues will be in the range of $250 to $265 million;
  • U.S. XIAFLEX net revenues will be in the range of $65 to $75 million; 
  • Ex-U.S. and deferred revenues for XIAFLEX will be in the range of $10 to $15 million;
  • Research and development spending on a non-GAAP basis will be in the range of $45 to $55 million;
  • Selling, general and administrative expenses on a non-GAAP basis will be in the range of $185 to $195 million;
  • Net interest expense on a non-GAAP basis will be in the range of $3 to 4 million; and, 
  • Net income on a non-GAAP basis will be in the range of $18 to $23 million.
  • Research and development and Selling, general and administrative expenses referred to above for 2013 exclude approximately $3 and $13 million, respectively, of estimated costs related to employee stock based compensation.  The Company excludes these costs because they constitute non-cash expenditures that are de
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Auxilium Announces Appointments to Enhance Leadership Team
    2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
    6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
    7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
    8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
    (Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
    (Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
    (Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
    Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
    ... Correct the Record and Provide Accurate Information to ... ... 20 VaxGen,Inc. (Pink Sheets: VXGN), (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), ... biotechnologies announced on,November 12, 2007 that their respective Boards of Directors ...
    ... ExL Pharma is pleased to announce the,fall ... leading issues that are,impacting the pharmaceutical industry today. ... networking opportunities for Clinical,Marketing, R&D, and Medical Affairs ... technology companies. Listed below are details on ...
    ... Tools Experience to the Leader in ... Cellular Bioenergetic Profiling, N. ... tools for real-time measurement of cellular,bioenergetics in microplates, announced today ... the company,s Board of,Directors. In this position, Keegan will apply ...
    Cached Biology Technology:VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2
    (Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
    (Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
    (Date:7/10/2014)... -- Acuity Market Intelligence today released forecasts from "The Global ... global market for National Electronic ID (eID) programs will generate ... time, the number of National eID cards in circulation will ... , with its vast population, will dominate the market ... Europe trails a distant second at ...
    Breaking Biology News(10 mins):Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
    ... Through an innovative feat of plant biotechnology and vaccine ... University have successfully turned tobacco plants into vaccine production ... vaccine elicits a protective immune response in guinea pigs. ... the future development of a new vaccine for human ...
    ... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
    ... Just as baby mammals depend on their mothers' milk, ... themselves by stripping off and eating the fat-rich outer ... team of researchers that includes University of Michigan biologist ... issue (April 13) of the journal Nature. , Hatchlings ...
    Cached Biology News:Plant-derived vaccines safeguard against deadly plague 2Plant-derived vaccines safeguard against deadly plague 3Do plants have the potential to vaccinate against HIV? 2African amphibians make extreme parental sacrifice: The skin off their backs 2African amphibians make extreme parental sacrifice: The skin off their backs 3
    MpV17 transgene, murine homolog, glomerulosclerosis...
    Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
    Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
    Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
    Biology Products: